Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
Compounds represented by formula (Ia) or (Ib) and wherein R and R 1 are as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.
1. A method for treating a cancer, the method comprising administering to a mammal in need thereof an effective amount of a compound represented by the following formula:
wherein
R is a group —COR a , —CONHR a or —CONR a R b wherein R a and R b are, each independently, hydrogen or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl or; together with the nitrogen atom to which they are bonded, R a and R b may form an optionally substituted 5 or 6 membered heterocycle optionally containing one additional heteroatom or heteroatomic group selected among N, NH, O or S; and
R 1 is tert-butyl;
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer, and Kaposi's sarcoma.
3. The method according to claim 1 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.
4. The method according to claim 1 wherein the mammal in need thereof is a human.
5. A compound represented by the following formula:
wherein
R is a group —COR a , —CONHR a or —CONR a R b wherein R a and R b are, each independently, hydrogen or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl or; together with the nitrogen atom to which they are bonded, R a and R b may form an optionally substituted 5 or 6 membered heterocycle optionally containing one additional heteroatom or heteroatomic group selected among N, NH, O or S; and
R 1 is tert-butyl;
or a pharmaceutically acceptable salt thereof.
6. A compound of formula (Ia) according to claim 5 , wherein R is a group —COR a with R a as 4-fluorophenyl or cyclobutyl.
7. A compound of claim 5 , wherein any of R a and R b is further substituted in one or more of their free positions, by groups independently selected from halogen, nitro, oxo groups (═O), cyano, alkyl, perfluorinated alkyl, perfluorinated alkoxy, alkenyl, alkynyl, hydroxyalkyl, aryl, arylalkyl, heterocyclyl, cycloalkyl, hydroxy, alkoxy, aryloxy, heterocyclyloxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, amino, ureido, alkylamino, dialkylamino, arylamino, diarylamino, formylamino, alkylcarbonylamino, arylcarbonylamino, heterocyclylcarbonylamino, alkoxycarbonylamino, alkoxyimino, alkylsulfonylamino, arylsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocyclylcarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylthio and alkylthio.
8. A compound:
N-[5-(2,2-dimethylpropanoyl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluorobenzamide;
or a pharmaceutically acceptable salt thereof.
9. A library of two or more compounds of the following formula:
wherein
R is a group —COR a ,—CONHR a or —CONR a R b wherein R a and R b are, each, independently, hydrogen or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl or; together with the nitrogen atom to which they are bonded, R a and R b may form an optionally substituted 5 or 6 membered heterocycle optionally containing one additional heteroatom or heteroatomic group selected among N, NH, O or S; and
R 1 is tert-butyl;
or pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (Ia), as defined in claim 5 , and at least one pharmaceutically acceptable excipient, carrier and/or diluents.
11. A pharmaceutical composition according to claim 10 further comprising one or more chemotherapeutic agents.
12. A product or kit comprising a compound of formula (Ia) as defined in claim 5 or a pharmaceutical composition thereof as defined in claim 10 , and one or more chemotherapeutic agents.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound, as defined in claim 5 , and a chemotherapeutic agent selected from the group consisting of cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors, matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-grow factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, typoisomerase II inhibitors and mixtures thereof.
14. A product or kit comprising a compound of claim 5 , and a chemotherapeutic agent selected from the group consisting of cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors, matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-grow factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, typoisomerase II inhibitors and mixtures thereof, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
15. The method according to claim 1 wherein the cancer is a tumor.
16. The method according to claim 15 , wherein the tumor is selected from the group consisting of hematopoietic tumors of lymphoid lineage, hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanomas, seminomas, teratocarcinomas, osteosarcomas, thyroid follicular cancer, and Kaposi's sarcoma.